Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jane Wrigley"'
Autor:
Jane Wrigley, Rajendra Kumari, Jason R. King, Maya Jetha, Yinfei Yin, Simon Jiang, Joyce Afrakoma Obeng
Publikováno v:
Cancer Research. 79:87-87
BACKGROUND: Checkpoint inhibitors have shown promising therapeutic benefit in various cancer types, but more advanced preclinical models are required to combat resistance and evaluate opportunities for combination treatments. Subcutaneous syngeneic m
Autor:
Anthony Oakden, Yinfei Yin, Davy Xuesong Ouyang, Rajendra Kumari, Wubin Qian, Bin Fan, Jane Wrigley, Anne T. Collins, Jason Davis, Chira Roberts, Jie Cai
Publikováno v:
Cancer Research. 79:1060-1060
BACKGROUND: Prostate cancer is one of the most common cancer worldwide with limited treatment options and very poor prognosis. Surgery, chemo therapy such as docetaxel (Taxotere®) and targeted therapies such as abiraterone (Zytiga®) and enzalutamid
Autor:
Jane Wrigley, Roslynn Mertens
Publikováno v:
Newborn and Infant Nursing Reviews. 10:138-142
Legal action against nurses and physicians regarding obstetrics and neonatal patients remains a significant concern when the outcome of a pregnancy is not as expected. Obstetric-related cases historically have sustained the highest median payment amo
Autor:
Rajendra Kumari, Sumanjeet Malhi, Jamie Wood, Yinfei Yin, Stephanie Morton, Jane Wrigley, Louise Wainwright, Simon H Jiang
Publikováno v:
Cancer Research. 78:5033-5033
BACKGROUND: Pre-clinical tumour models lack human stromal cells and are inadequate for the assessment of novel tumour microenvironment targeted therapies. An increase in combination opportunities requires a higher throughput in vitro assay that utili
Autor:
Stephanie Morton, Sumanjeet Malhi, Jane Wrigley, Jason R. King, Lucy Harris, Simon Jiang, Yinfei Yin, Louise Wainwright, Jamie Wood, Rajendra Kumari
Publikováno v:
Molecular Cancer Therapeutics. 17:A213-A213
Background: Preclinical in vitro and in vivo tumor models lack human stromal cells and are inadequate for the assessment of novel tumor microenvironment-targeted therapies. Here we report on a 3D-tumor growth assay (3D-TGA) in which patient-derived t
Autor:
Jason R. King, Louise Wainwright, Jamie Wood, Louise Woolley, Jane Wrigley, Simon Jiang, Vicky Lacey, Nektaria Papadopoulou, Rajendra Kumari, Sumanjeet Malhi
Publikováno v:
Molecular Cancer Therapeutics. 17:A010-A010
Background: Hepatocellular carcinoma (HCC) is an aggressive disease with limited therapeutic treatment options. Checkpoint inhibitors are widely being evaluated in numerous cancers including HCC, but suitable preclinical models are required. Subcutan
Autor:
Rajendra Kumari, Andrew N. J. McKenzie, Kelly Jones, Nektaria Papadopoulou, Jason R. King, Jane Wrigley, Anne T. Collins, Louise Wainwright
Publikováno v:
Cancer Research. 77:2824-2824
Background: Prostate cancer is the second most common cancer worldwide for males, and the fourth most common cancer overall, with more than a million new cases diagnosed. However, progress toward understanding the biology of prostate cancer and the d
Publikováno v:
Circulation. 102:2479-2483
Background —Hyperhomocysteinemia is an independent risk factor for coronary heart disease (CHD). Dietary supplementation with B vitamins lowers plasma homocysteine by up to 30%. However, little is known about the potential beneficial effects of hom
Autor:
Nektaria Papadopoulou, Neil Williams, Russell Garland, Simon Jiang, Jane Wrigley, Andrew McKenzie, Rajendra Kumari, Kelly Jones
Publikováno v:
Cancer Immunology Research. 4:A140-A140
Introduction: Syngeneic models are widely used to model the impact of cancer immunotherapy on tumor growth and tumor invading leucocytes (TILs), and the majority of such work is typically carried out in the subcutaneous setting. However, orthotopic m
Autor:
Nektaria Papadopoulou, Qian Shi, Neil Williams, Jane Wrigley, Andrew McKenzie, Simon Jiang, Russell Garland, Rajendra Kumari, Yinfei Yin, Jason R. King
Publikováno v:
Cancer Research. 76:3994-3994
INTRODUCTION: Recent progress in the field of cancer immunotherapy have made it possible to translate several emerging immunostimulatory strategies, e.g. anti-CTLA-4, and anti-PD-1 into the clinic resulting in promising clinical benefits. In addition